Skip to content

Allergan supports DARPin technology through license and option agreements with Molecular Partners

Allergan supports DARPin technology through license and option agreements with Molecular Partners
Allergan Inc., (NYSE:AGN) and Molecular Partners AG, a privately owned Swiss company, have announced the signing of two business transactions aimed at expanding the development and commercialisation of therapeutic products for the treatment of ophthalmic diseases. The deals cover the application of the Swiss company’s technology platform in “DARPins”, next generation protein drugs developed to overcome the limitations of monoclonal antibodies. While detailed terms were not disclosed, Molecular Partners AG are expected to earn combined upfront payments of $62.5 million and be eligible for additional success-based payments of up to $1.4 billion in aggregate development, regulatory and sales milestones and tiered royalties on future product sales.